Loading
A phase 2 trial of Temoporfin in Extrahepatic cholangiocarcinoma, run by Chinese University of Hong Kong, completed.
Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers is a phase 2 interventional study registered as NCT03003065 by Chinese University of Hong Kong, with 10 participants recorded, started 2014-03-28 and reaching its primary completion in 2023-04-12. Interventions recorded: Temoporfin. Conditions recorded: Cholangiocarcinoma, Tumor, Klatskin Tumor.
Linked to the drug Temoporfin because the registry names it among its interventions and Extrahepatic cholangiocarcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Temoporfin and the tag pipeline.
Shares Temoporfin and the tag pipeline.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/